Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
29 avr. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in Phase 2 studySystemic...